Last year, China SXT Pharmaceuticals Inc generated 1.08M USD for its biggest-performing segment, Regular TCMP. The People's Republic of China made the largest contribution, accounting for 1.14M USD last year.

By Business

Revenue

Proportion

Annual

Annual

Quarterly

Regular TCMP

Advanced TCMP

Others

TCMHS

Fine TCMP

FY2026

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

Regular TCMP

1.08M(95.02%)

1.44M(82.86%)

945.00K(49.00%)

697.52K(35.38%)

793.43K(30.49%)

1.45M(30.36%)

2.28M(44.15%)

2.86M(40.73%)

Advanced TCMP

49.52K(4.35%)

258.42K(14.84%)

946.01K(49.05%)

656.94K(33.32%)

1.16M(44.70%)

1.77M(37.10%)

1.58M(30.65%)

3.63M(51.79%)

Others

7.14K(0.63%)

--(--)

Others

--(--)

40.02K(2.30%)

13.15K(0.68%)

--(--)

TCMHS

--(--)

24.17K(1.25%)

502.43K(25.48%)

245.96K(9.45%)

974.82K(20.40%)

267.47K(5.18%)

--(--)

Fine TCMP

--(--)

166.00(0.01%)

114.79K(5.82%)

399.77K(15.36%)

579.79K(12.14%)

1.03M(20.02%)

524.25K(7.48%)

By Region

Revenue

Proportion

Annual

Annual

Quarterly

People's Republic of China

FY2026

FY2025

FY2024

FY2023

FY2022

FY2021

People's Republic of China

1.14M(100.00%)

1.74M(100.00%)

1.93M(100.00%)

1.97M(100.00%)

2.60M(100.00%)

4.78M(100.00%)